FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018375466> ?p ?o ?g. }

• W2018375466 endingPage "334" @default.
• W2018375466 startingPage "327" @default.
• W2018375466 abstract "Background Shorter than traditional 7- to 14-day treatment regimens have demonstrated efficacy in treatment of an acute exacerbation of chronic bronchitis (AECB). Objective Perform a clinical efficacy study comparing 5 days of cefprozil therapy to 10 days of clarithromycin in treating an AECB. Methods A multicenter, randomized, double-blind study comparing efficacy and safety of cefprozil, 500 mg twice daily, for 5 days with clarithromycin, 500 mg twice daily, for 10 days in treatment of 295 subjects with AECB. Concomitantly, among all treated subjects, 39% (115 of 295) had a history of chronic obstructive pulmonary disease/emphysema; 21% (62 of 295) had a history of asthma/reactive airway disease; and 31% (90 of 295) had environmental allergies. Results There were no statistically significant differences among clinically evaluable subjects' cure rates; 82% (109 of 133) treated with cefprozil versus 85% (105 of 123) treated with clarithromycin were cured at test-of-cure visit (95% confidence interval, −12.0 to 5.1%). Clinical cure rates at end of study were 80% and 81%, respectively (95% confidence interval, −10.8 to 7.9%). Before treatment, 99% (85 of 86) of Gram-positive organisms isolated were susceptible to cefprozil and 78% (67 of 86) were susceptible to clarithromycin. A total of 84% (96 of 114) of Gram-negative organisms were susceptible to cefprozil and 63% (72 of 114) were susceptible to clarithromycin. Of clinically evaluableStreptococcus pneumoniae-infected subjects, 100% (11 of 11) of cefprozil subjects and 93% (14 of 15) of clarithromycin subjects experienced clinical cure. The most frequently reported adverse effects were nausea, 5% (7 of 150), and diarrhea, 9% (14 of 150), for cefprozil. For clarithromycin, the adverse effects were nausea, 8% (11 of 145); diarrhea, 12% (18 of 145); taste perversion, 8% (11 of 145); and dry mouth, 5% (7 of 145). Conclusions Five days of cefprozil is as effective as 10 days of clarithromycin for treatment of an AECB. Shorter than traditional 7- to 14-day treatment regimens have demonstrated efficacy in treatment of an acute exacerbation of chronic bronchitis (AECB). Perform a clinical efficacy study comparing 5 days of cefprozil therapy to 10 days of clarithromycin in treating an AECB. A multicenter, randomized, double-blind study comparing efficacy and safety of cefprozil, 500 mg twice daily, for 5 days with clarithromycin, 500 mg twice daily, for 10 days in treatment of 295 subjects with AECB. Concomitantly, among all treated subjects, 39% (115 of 295) had a history of chronic obstructive pulmonary disease/emphysema; 21% (62 of 295) had a history of asthma/reactive airway disease; and 31% (90 of 295) had environmental allergies. There were no statistically significant differences among clinically evaluable subjects' cure rates; 82% (109 of 133) treated with cefprozil versus 85% (105 of 123) treated with clarithromycin were cured at test-of-cure visit (95% confidence interval, −12.0 to 5.1%). Clinical cure rates at end of study were 80% and 81%, respectively (95% confidence interval, −10.8 to 7.9%). Before treatment, 99% (85 of 86) of Gram-positive organisms isolated were susceptible to cefprozil and 78% (67 of 86) were susceptible to clarithromycin. A total of 84% (96 of 114) of Gram-negative organisms were susceptible to cefprozil and 63% (72 of 114) were susceptible to clarithromycin. Of clinically evaluableStreptococcus pneumoniae-infected subjects, 100% (11 of 11) of cefprozil subjects and 93% (14 of 15) of clarithromycin subjects experienced clinical cure. The most frequently reported adverse effects were nausea, 5% (7 of 150), and diarrhea, 9% (14 of 150), for cefprozil. For clarithromycin, the adverse effects were nausea, 8% (11 of 145); diarrhea, 12% (18 of 145); taste perversion, 8% (11 of 145); and dry mouth, 5% (7 of 145). Five days of cefprozil is as effective as 10 days of clarithromycin for treatment of an AECB." @default.
• W2018375466 created "2016-06-24" @default.
• W2018375466 creator A5068576644 @default.
• W2018375466 creator A5071309765 @default.
• W2018375466 date "2001-10-01" @default.
• W2018375466 modified "2023-09-27" @default.
• W2018375466 title "Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis" @default.
• W2018375466 cites W111700814 @default.
• W2018375466 cites W1998567508 @default.
• W2018375466 cites W2012519534 @default.
• W2018375466 cites W2017333014 @default.
• W2018375466 cites W2018010902 @default.
• W2018375466 cites W2037567282 @default.
• W2018375466 cites W2041972306 @default.
• W2018375466 cites W2069444366 @default.
• W2018375466 cites W2098041959 @default.
• W2018375466 cites W2098530825 @default.
• W2018375466 cites W2108921279 @default.
• W2018375466 cites W2114189566 @default.
• W2018375466 cites W2120420331 @default.
• W2018375466 cites W2123320389 @default.
• W2018375466 cites W2129097224 @default.
• W2018375466 cites W2149144558 @default.
• W2018375466 cites W2158583961 @default.
• W2018375466 cites W2322552326 @default.
• W2018375466 cites W2342459977 @default.
• W2018375466 cites W4244703446 @default.
• W2018375466 doi "https://doi.org/10.1016/s1081-1206(10)62248-x" @default.
• W2018375466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11686426" @default.
• W2018375466 hasPublicationYear "2001" @default.
• W2018375466 type Work @default.
• W2018375466 sameAs 2018375466 @default.
• W2018375466 citedByCount "13" @default.
• W2018375466 countsByYear W20183754662013 @default.
• W2018375466 crossrefType "journal-article" @default.
• W2018375466 hasAuthorship W2018375466A5068576644 @default.
• W2018375466 hasAuthorship W2018375466A5071309765 @default.
• W2018375466 hasConcept C126322002 @default.
• W2018375466 hasConcept C2776409635 @default.
• W2018375466 hasConcept C2776962512 @default.
• W2018375466 hasConcept C2777014857 @default.
• W2018375466 hasConcept C2779993553 @default.
• W2018375466 hasConcept C2992694001 @default.
• W2018375466 hasConcept C3019249092 @default.
• W2018375466 hasConcept C44249647 @default.
• W2018375466 hasConcept C501593827 @default.
• W2018375466 hasConcept C71924100 @default.
• W2018375466 hasConcept C86803240 @default.
• W2018375466 hasConcept C89423630 @default.
• W2018375466 hasConceptScore W2018375466C126322002 @default.
• W2018375466 hasConceptScore W2018375466C2776409635 @default.
• W2018375466 hasConceptScore W2018375466C2776962512 @default.
• W2018375466 hasConceptScore W2018375466C2777014857 @default.
• W2018375466 hasConceptScore W2018375466C2779993553 @default.
• W2018375466 hasConceptScore W2018375466C2992694001 @default.
• W2018375466 hasConceptScore W2018375466C3019249092 @default.
• W2018375466 hasConceptScore W2018375466C44249647 @default.
• W2018375466 hasConceptScore W2018375466C501593827 @default.
• W2018375466 hasConceptScore W2018375466C71924100 @default.
• W2018375466 hasConceptScore W2018375466C86803240 @default.
• W2018375466 hasConceptScore W2018375466C89423630 @default.
• W2018375466 hasIssue "4" @default.
• W2018375466 hasLocation W20183754661 @default.
• W2018375466 hasLocation W20183754662 @default.
• W2018375466 hasOpenAccess W2018375466 @default.
• W2018375466 hasPrimaryLocation W20183754661 @default.
• W2018375466 hasRelatedWork W179815994 @default.
• W2018375466 hasRelatedWork W184606256 @default.
• W2018375466 hasRelatedWork W1996871490 @default.
• W2018375466 hasRelatedWork W2018375466 @default.
• W2018375466 hasRelatedWork W2026688724 @default.
• W2018375466 hasRelatedWork W2053990863 @default.
• W2018375466 hasRelatedWork W2076574401 @default.
• W2018375466 hasRelatedWork W2146831409 @default.
• W2018375466 hasRelatedWork W2402158757 @default.
• W2018375466 hasRelatedWork W264790527 @default.
• W2018375466 hasVolume "87" @default.
• W2018375466 isParatext "false" @default.
• W2018375466 isRetracted "false" @default.
• W2018375466 magId "2018375466" @default.
• W2018375466 workType "article" @default.